An evaluation of emerging vaccines for childhood pneumococcal pneumonia

BMC Public Health

Volumn 11, Issue SUPPL. 3, 2011, Pages

  Webster, Julia ^a   Theodoratou, Evropi ^a   Nair, Harish ^a,b   Seong, Ang Choon ^a   Zgaga, Lina ^a   Huda, Tanvir ^c   Johnson, Hope L ^d   Madhi, Shabir ^e   Rubens, Craig ^f   Zhang, Jian Shayne F ^a   El Arifeen, Shams ^c   Krause, Ryoko ^g   Jacobs, Troy A ^h   Brooks, Abdullah W ^c,d   Campbell, Harry ^a   Rudan, Igor ^a,i  

^a UNIVERSITY OF EDINBURGH   (United Kingdom)

^b PUBLIC HEALTH FOUNDATION OF INDIA   (India)

^c INTERNATIONAL CENTRE FOR DIARRHOEAL DISEASE RESEARCH   (Bangladesh)

^d JOHNS HOPKINS BLOOMBERG SCHOOL OF PUBLIC HEALTH   (United States)

^e UNIVERSITY OF THE WITWATERSRAND   (South Africa)

^f Seattle Children's Met Park West   (United States)

^g International Federation of Pharmaceutical Manufacturers and Associations   (Switzerland)

^h UNITED STATES AGENCY FOR INTERNATIONAL DEVELOPMENT   (United States)

ⁱ UNIVERSITY OF SPLIT   (Croatia)

Author keywords

[No Author keywords available]

Indexed keywords

PNEUMOCOCCUS VACCINE; VACCINE;

CHILD; COST BENEFIT ANALYSIS; ECONOMICS; EVALUATION; HEALTH; HUMAN; IMMUNOLOGY; MORTALITY; REVIEW; STREPTOCOCCUS PNEUMONIA; STREPTOCOCCUS PNEUMONIAE;

CHILD; COST-BENEFIT ANALYSIS; HUMANS; PNEUMOCOCCAL VACCINES; PNEUMONIA, PNEUMOCOCCAL; STREPTOCOCCUS PNEUMONIAE; VACCINES, CONJUGATE; WORLD HEALTH;

EID: 79954555975     PISSN: None     EISSN: 14712458     Source Type: Journal    
DOI: 10.1186/1471-2458-11-S3-S26     Document Type: Article

References (65)

1. Global, regional, and national causes of child mortality in 2008: a systematic analysis. RE Black S Cousens HL Johnson JE Lawn I Rudan DG Bassani P Jha H Campbell CF Walker R Cibulskis T Eisele L Liu C Mathers, Lancet 2010 375 9730 1969 1987 10.1016/S0140-6736(10)60549-1 20466419
2. Improving Global Health by Preventing Pneumococcal Disease. Report from the All-Party Parliamentary Group on Pneumococcal Disease Prevention in the Developing World 2008
3. Burden of disease caused by Streptococcus pneumoniae in children younger than 5 years: global estimates. KL O'Brien LJ Wolfson JP Watt E Henkle M Deloria-Knoll N McCall E Lee K Mulholland OS Levine T Cherian, Lancet 2009 374 893 902 19748398
4. Pneumococcal conjugate vaccines for preventing vaccine-type invasive pneumococcal disease and pneumonia with consolidation on x-ray in children under two years of age. MG Lucero VE Dulalia RN Parreno DM Lim-Quianzon H Nohynek H Makela G Williams, Cochrane Database Syst Rev 2004 D004977 15495133
5. Pneumococcal conjugate vaccines for preventing vaccine-type invasive pneumococcal disease and X-ray defined pneumonia in children less than two years of age. MG Lucero VE Dulalia LT Nillos G Williams RA Parreno H Nohynek ID Riley H Makela, Cochrane Database Syst Rev 2009 D004977 19821336
6. Pneumococcal Regional Serotype Distribution for Pneumococcal AMC TPP. GAVI's PneumoADIP, 2008
7. http://www.preventpneumo.org/index.cfm 21-5-2009. 21-5-2009
8. The contribution of specific pneumococcal serogroups to different disease manifestations: implications for conjugate vaccine formulation and use, part II. WP Hausdorff J Bryant C Kloek PR Paradiso GR Siber, Clin Infect Dis 2000 30 122 140 10.1086/313609 10619741 (Pubitemid 30067070)
9. Childhood pneumonia and diarrhoea: setting our priorities right. I Rudan S El Arifeen RE Black H Campbell, Lancet Infect Dis 2007 7 56 61 10.1016/S1473-3099(06)70687-9 17182344 (Pubitemid 44917782)
10. Setting priorities in global child health research investments: assessment of principles and practice. I Rudan J Gibson L Kapiriri MA Lansang AA Hyder J Lawn GL Darmstadt S Cousens ZA Bhutta KH Brown SY Hess M Black JM Gardner J Webster I Carneiro D Chandramohan M Kosek CF Lanata M Tomlinson M Chopra S Ameratunga H Campbell S El Arifeen RE Black, Croat Med J 2007 48 595 604 17948946 (Pubitemid 350022000)
11. Setting priorities in global child health research investments: addressing values of stakeholders. L Kapiriri M Tomlinson M Chopra S El Arifeen RE Black I Rudan, Croat Med J 2007 48 618 627 17948948 (Pubitemid 350022002)
12. Setting priorities in global child health research investments: universal challenges and conceptual framework. I Rudan M Chopra L Kapiriri J Gibson LM Ann I Carneiro S Ameratunga AC Tsai KY Chan M Tomlinson SY Hess H Campbell S El Arifeen RE Black, Croat Med J 2008 49 307 317 10.3325/cmj.2008.3.307 18581609 (Pubitemid 351955763)
13. The complex challenge of setting priorities in health research investments. I Rudan, Indian J Med Res 2009 129 351 353 19535827
14. Research priorities for health of people with disabilities: an expert opinion exercise. M Tomlinson L Swartz A Officer KY Chan I Rudan S Saxena, Lancet 2009 374 1857 1862 10.1016/S0140-6736(09)61910-3 19944866
15. Setting research priorities to reduce global mortality from childhood diarrhoea by 2015. O Fontaine M Kosek S Bhatnagar C Boschi-Pinto KY Chan C Duggan H Martinez H Ribeiro NC Rollins MA Salam M Santosham JD Snyder AC Tsai B Vargas I Rudan, PLoS Med 2009 6 41 10.1371/journal.pmed.1000041 19278292
16. Research priorities to reduce global mortality from newborn infections by 2015. R Bahl J Martines N Ali MK Bhan W Carlo KY Chan GL Darmstadt DH Hamer JE Lawn DD McMillan P Mohan V Paul AC Tsai CG Victora MW Weber AK Zaidi I Rudan, Pediatr Infect Dis J 2009 28 43 S48 10.1097/INF.0b013e31819588d7 19106763
17. Setting priorities in child health research investments for South Africa. M Tomlinson M Chopra D Sanders D Bradshaw M Hendricks D Greenfield RE Black S El Arifeen I Rudan, PLoS Med 2007 4 259 10.1371/journal.pmed.0040259 17760497
18. Setting priorities for global mental health research. M Tomlinson I Rudan S Saxena L Swartz AC Tsai V Patel, Bull World Health Organ 2009 87 438 446 10.2471/BLT.08.054353 19565122
19. Setting priorities in global child health research investments: guidelines for implementation of CHNRI method. I Rudan JL Gibson S Ameratunga S El Arifeen ZA Bhutta M Black RE Black KH Brown H Campbell I Carneiro KY Chan D Chandramohan M Chopra S Cousens GL Darmstadt GJ Meeks SY Hess AA Hyder L Kapiriri M Kosek CF Lanata MA Lansang J Lawn M Tomlinson AC Tsai J Webster, Croat Med J 2008 49 720 733 10.3325/cmj.2008.49.720 19090596
20. Immunogenicity, efficacy, safety and effectiveness of pneumococcal conjugate vaccines (1998-2006). F Oosterhuis-Kafeja P Beutels P Van Damme, Vaccine 2007 25 2194 2212 10.1016/j.vaccine.2006.11.032 17267077 (Pubitemid 46227685)
21. -2009 http://www.ema.europa.eu/humandocs/Humans/EPAR/synflorix/synflorix. htm 14-5-2009
22. Current knowledge regarding the investigational 13-valent pneumococcal conjugate vaccine. EC Dinleyici ZA Yargic, Expert Rev Vaccines 2009 8 977 986 10.1586/erv.09.68 19627181
23. Advances in pneumococcal vaccines: the 13-valent pneumococcal conjugate vaccine received market authorization in Europe. RR Reinert P Paradiso B Fritzell, Expert Rev Vaccines 2010 9 229 236 10.1586/erv.10.6 20218848
24. The contribution of specific pneumococcal serogroups to different disease manifestations: implications for conjugate vaccine formulation and use, part II. WP Hausdorff J Bryant C Kloek PR Paradiso GR Siber, Clin Infect Dis 2000 30 122 140 10.1086/313609 10619741 (Pubitemid 30067070)
25. Which pneumococcal serogroups cause the most invasive disease: implications for conjugate vaccine formulation and use, part I. WP Hausdorff J Bryant PR Paradiso GR Siber, Clin Infect Dis 2000 30 100 121 10.1086/313608 10619740 (Pubitemid 30067069)
26. Serotype replacement in perspective. R Dagan, Vaccine 2009 27 Suppl 3 22 C24 10.1016/j.vaccine.2009.06.004 19545935
27. PspA, a surface protein of Streptococcus pneumoniae, is capable of eliciting protection against pneumococci of more than one capsular type. LS McDaniel JS Sheffield P Delucchi DE Briles, Infect Immun 1991 59 222 228 1987036
28. Immunization of mice with single PspA fragments induces antibodies capable of mediating complement deposition on different pneumococcal strains and cross-protection. AT Moreno ML Oliveira DM Ferreira PL Ho M Darrieux LC Leite JM Ferreira Jr. FC Pimenta AL Andrade EN Miyaji, Clin Vaccine Immunol 2010 17 439 446 10.1128/CVI.00430-09 20089795
29. Evaluation and improvement of real-time PCR assays targeting lytA, ply, and psaA genes for detection of pneumococcal DNA. MG Carvalho ML Tondella K McCaustland L Weidlich L McGee LW Mayer A Steigerwalt M Whaley RR Facklam B Fields G Carlone EW Ades R Dagan JS Sampson, J Clin Microbiol 2007 45 2460 2466 10.1128/JCM.02498-06 17537936 (Pubitemid 47295474)
30. Vaccines in the era of genomics: the pneumococcal challenge. MA Barocchi S Censini R Rappuoli, Vaccine 2007 25 2963 2973 10.1016/j.vaccine.2007.01.065 17324490 (Pubitemid 46486683)
31. Use of a whole genome approach to identify vaccine molecules affording protection against Streptococcus pneumoniae infection. TM Wizemann JH Heinrichs JE Adamou AL Erwin C Kunsch GH Choi SC Barash CA Rosen HR Masure E Tuomanen A Gayle YA Brewah W Walsh P Barren R Lathigra M Hanson S Langermann S Johnson S Koenig, Infect Immun 2001 69 1593 1598 10.1128/IAI.69.3.1593-1598.2001 11179332 (Pubitemid 32187614)
32. Bacterial genomes pave the way to novel vaccines. A Meinke T Henics E Nagy, Curr Opin Microbiol 2004 7 314 320 10.1016/j.mib.2004.04.008 15196501 (Pubitemid 38758074)
33. Discovery of a novel class of highly conserved vaccine antigens using genomic scale antigenic fingerprinting of pneumococcus with human antibodies. C Giefing AL Meinke M Hanner T Henics MD Bui D Gelbmann U Lundberg BM Senn M Schunn A Habel B Henriques-Normark A Ortqvist M Kalin A von Gabain E Nagy, J Exp Med 2008 205 117 131 10.1084/jem.20071168 18166586 (Pubitemid 351185720)
34. Efficacy of nine-valent pneumococcal conjugate vaccine against pneumonia and invasive pneumococcal disease in The Gambia: randomised, double-blind, placebo-controlled trial. FT Cutts SM Zaman G Enwere S Jaffar OS Levine JB Okoko C Oluwalana A Vaughan SK Obaro A Leach KP McAdam E Biney M Saaka U Onwuchekwa F Yallop NF Pierce BM Greenwood RA Adegbola, Lancet 2005 365 1139 1146 10.1016/S0140-6736(05)71876-6 15794968 (Pubitemid 40417563)
35. Safety and reactogenicity of the new 10-valent pneumococcal non-typeable Haemophilus influenza influenza protein D conjugate vaccine (PHiD-CV). M Knuf D Grunert J Wysocki,, et al. 6th International Symposium on Pneumococci & Pneumococcal Diseases 2008
36. Co-administration of the new 10-valent pneumococcal non-typeable Haemophilus influenzae protein D conjugate vaccine (PHiD-CV) with other routine paediatric vaccines. JC Tejedor J Garcia-Sicilia D Grunert,, et al. 6th International Symposium on Pneumococci & Pneumococcal Diseases 2008
37. Phase IIIa randomized, controlled study to assess the immunogenicity of GlaxoSmithKline (GSK) Biologicals' 10-valent pneumococcal conjugate vaccine, when administered as a 3-dose primary immunization course before 6 months of age. 2007 http://download.gsk-clinicalstudyregister.com/files/20059.pdf 22-5-2009
38. Phase 1 trial of a 13-valent pneumococcal conjugate vaccine in healthy adults. DA Scott SF Komjathy BT Hu S Baker LA Supan CA Monahan W Gruber GR Siber SP Lockhart, Vaccine 2007 25 6164 6166 10.1016/j.vaccine.2007.06.004 17629361 (Pubitemid 47088041)
39. Phase 1 trial of 13-valent pneumococcal conjugate vaccine in Japanese adults. D Scott J Ruckle M Dar S Baker H Kondoh S Lockhart, Pediatr Int 2008 50 295 299 10.1111/j.1442-200X.2008.02593.x 18533940 (Pubitemid 351781510)
40. Pfizer clinical trial listings - Pneumococcal vaccine. 2009 https://kfweb2.kraftfoods.com/ClinicalTrialListings?query=Infection 22-5-2009
41. Press release - Pfizers Prevenar 13 receives first approval. 2010 http://www.Pfizer.com/news?nav=display&navTo=/Pfizer-html/home/news/ pressreleases/2009/1247572971477.html 4-9-2009
42. -2009 http://www.ema.europa.eu/humandocs/Humans/EPAR/Prevenar13/ Prevenar13.htm
43. -2010 http://www.fda.gov/BiologicsBloodVaccines/Vaccines/ ApprovedProducts/ucm201667.htm
44. -2009 http://www.intercell.com/main/forbeginners/news/news-full/article/ intercell-starts-a-phase-i-clinical-trial-for-a-new-streptococcus-pneumoniae- vaccine/ 23-4-2009
45. -2009 http://www.sabin.org/files/alderson-pvp-istanbul-ppt-readonly.pdf
46. Decline in pneumonia admissions after routine childhood immunisation with pneumococcal conjugate vaccine in the USA: a time-series analysis. CG Grijalva JP Nuorti PG Arbogast SW Martin KM Edwards MR Griffin, Lancet 2007 369 1179 1186 10.1016/S0140-6736(07)60564-9 17416262 (Pubitemid 46527876)
47. Systematic evaluation of serotypes causing invasive pneumococcal disease among children under five: the pneumococcal global serotype project. HL Johnson M Deloria-Knoll OS Levine SK Stoszek HL Freimanis R Reithinger LR Muenz KL O'Brien, PLoS Med 2010 7 10.1371/journal.pmed.1000348 20957191
48. A trial of a 9-valent pneumococcal conjugate vaccine in children with and those without HIV infection. KP Klugman SA Madhi RE Huebner R Kohberger N Mbelle N Pierce, N Engl J Med 2003 349 1341 1348 10.1056/NEJMoa035060 14523142 (Pubitemid 37186212)
49. Long-term immunogenicity and efficacy of a 9-valent conjugate pneumococcal vaccine in human immunodeficient virus infected and non-infected children in the absence of a booster dose of vaccine. SA Madhi P Adrian L Kuwanda W Jassat S Jones T Little A Soininen C Cutland KP Klugman, Vaccine 2007 25 2451 2457 10.1016/j.vaccine.2006.09.019 17023095 (Pubitemid 46389429)
50. Impact of human immunodeficiency virus type 1 on the disease spectrum of Streptococcus pneumoniae in South African children. SA Madhi K Petersen A Madhi A Wasas KP Klugman, Pediatr Infect Dis J 2000 19 1141 1147 10.1097/00006454- 200012000-00004 11144373 (Pubitemid 32003356)
51. Direct and Indirect Effects of Routine Vaccination of Children With 7-Valent Pneumococcal Conjugate Vaccine on Incidence of Invasive Pneumococcal Disease - United States. A Reingold J Hadler MM Farley,, et al. CAB - Abstract 2003
52. Invasive pneumococcal disease in children 5 years after conjugate vaccine introduction - eight states, 1998-2005. MMWR Morb Mortal Wkly Rep 2008 57 144 148 18272956
53. The potential for using protein vaccines to protect against otitis media caused by Streptococcus pneumoniae. DE Briles SK Hollingshead GS Nabors JC Paton A Brooks-Walter, Vaccine 2000 19 Suppl 1 87 S95 10.1016/S0264-410X(00)00285-1 11163470
54. -2006 http://www.vaccineamc.org/ 17-3-2009
55. Achieving universal coverage with health interventions. CG Victora K Hanson J Bryce JP Vaughan, Lancet 2004 364 1541 1548 10.1016/S0140-6736(04) 17279-6 15500901 (Pubitemid 39410422)
56. Lombok Hepatitis B Model Immunization Project: toward universal infant hepatitis B immunization in Indonesia. TA Ruff DM Gertig BF Otto ID Gust A Sutanto TI Soewarso N Kandun IC Marschner JE Maynard, J Infect Dis 1995 171 290 296 10.1093/infdis/171.2.290 7844364
57. Acute respiratory diseases: a study on health inequalities. AM Chiesa MF Westphal M Akerman, Cad Saude Publica 2008 24 55 69 10.1590/S0102- 311X2008000100006 18209834
58. Invasive pneumococcal disease among infants before and after introduction of pneumococcal conjugate vaccine. KA Poehling TR Talbot MR Griffin AS Craig CG Whitney E Zell CA Lexau AR Thomas LH Harrison AL Reingold JL Hadler MM Farley BJ Anderson W Schaffner, JAMA 2006 295 1668 1674 10.1001/jama.295.14.1668 16609088
59. Epidemiological differences among pneumococcal serotypes. WP Hausdorff DR Feikin KP Klugman, Lancet Infect Dis 2005 5 83 93 15680778 (Pubitemid 40174779)
60. Herd immunity and pneumococcal conjugate vaccine: a quantitative model. M Haber A Barskey W Baughman L Barker CG Whitney KM Shaw W Orenstein DS Stephens, Vaccine 2007 25 5390 5398 10.1016/j.vaccine.2007.04.088 17583392 (Pubitemid 46977530)
61. -2009 ftp://ftp.ng.afro.who.int/13thTFI/2005%20TFI%20CD/ Background%20Docs%20for%20TFI%20members/ Regional%20Lessons%20learned%20from%20New%20Vaccines.pdf 20-4-2009
62. Access to and utilisation of health services for the poor in Uganda: a systematic review of available evidence. SN Kiwanuka EK Ekirapa S Peterson O Okui MH Rahman D Peters GW Pariyo, Trans R Soc Trop Med Hyg 2008 102 1067 1074 10.1016/j.trstmh.2008.04.023 18565559
63. Community economic development and acute lower respiratory infection in children. AL Cunha PA Margolis S Wing, Journal of Health & Population in Developing Countries 2003 4 1 7
64. Hospitalization due to pneumonia: the influence of socioeconomic and pregnancy factors in a cohort of children in Southern Brazil. JA Cesar CG Victora IS Santos FC Barros EP Albernaz LM Oliveira JA Flores BL Horta E Weiderpass R Halpern, Rev Saude Publica 1997 31 53 61 9430926 (Pubitemid 126445299)
65. Respiratory syncytial virus infection. EA Simoes, Lancet 1999 354 847 852 10485741 (Pubitemid 29415599)